amyotrophic lateral sclerosis
Three patients with amyotrophic lateral sclerosis will be permitted to receive a second dose of stem cells delivered directly to the spinal cord, in a clinical trial being led by the University of Michigan’s Eva Feldman, M.D.
Synthetic Biologics Inc. (NYSE Amex: SYN) Thursday announced the release of its investor relations mobile iPhone App, called the “SYN IR” App, now available for free at the Apple App Store on the iPhone or iPad or at http://bit.ly/I9xDpW.
The first published results from an early-stage clinical trial show that spinal cord stem cells can be delivered safely into the spines of patients with the condition commonly known as Lou Gehrig’s disease, opening the door for further research on this innovative approach.
Pharma startup Adeona and its research partner report no safety issues related to high doses of zinc to slow the effects of Lou Gehrig’s Disease
In cells, as in cities, disposing of garbage and recycling anything that can be reused is an essential service. In both city and cell, health problems can arise when the process breaks down. New research […]